

## **Karolinska Development - Interim report January - March, invitation to conference call Friday, May 10**

**STOCKHOLM – May 7, 2013. Karolinska Development will publish its Interim report for January – March 2013 on Friday, May 10, 2013. The company will also host a conference call and an on-line presentation on the same day at 14.00 CET.**

Please dial in at the following number a few minutes before the start of the conference call:

- From Sweden: +46 (0)8 506 307 79
- From the US: +1 866 682 8490
- From the UK: +44 (0) 1452 555 131

The presentation will also be webcasted and can be accessed from the following web address:

[http://storm.zoomvisionmamato.com/player/karolinska\\_development/objects/143ch80p/](http://storm.zoomvisionmamato.com/player/karolinska_development/objects/143ch80p/)

Host: Torbjörn Bjerke, CEO.

**For further information, please contact:**

Benjamin Nordin, IRO, Karolinska Development AB

Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

### **TO THE EDITORS**

**About Karolinska Development AB**

Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 15 are in clinical development. For more information, please visit [www.karolinskadevelopment.com](http://www.karolinskadevelopment.com).

*Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.*